By now you have heard how GLP-1 agonists (the same compounds that make up Ozempic, Mounjaro, Wygovy) have changed the lives of millions of people suffering from weight loss and the adverse effects associated with it. Our clinically proven weight loss meds are wildly popular for a reason: They are effective. Patients enjoyed weight loss of 15%*. Not only that, clinical evidence has shown that patients had less depression, better cardiovascular health, and lower blood pressure, and lower cholesterol. **
● After 68 weeks of weekly semaglutide treatment, participants experienced an average body weight reduction of 15%. The semaglutide group saw a 14.9% decrease from baseline, compared to just 2.4% in the placebo group.
● * Cardiovascular Disease Risk Factors: Improvements in triglycerides and systolic blood pressure can begin with as little as 2-5% weight loss. For diastolic blood pressure and HDL cholesterol, benefits are seen with a 5-10% reduction in body weight.
● * Emotional Health & Confidence: Dietary interventions for obese individuals with depression may not only alleviate some depressive symptoms but also enhance their metabolic profile and reduce cardiovascular risks.